Stay updated with breaking news from Daptorum Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology
Regulatory News: Aptorum Group Limited , a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced that an interview... | April 22, 2022
By Michael Dabaie Aptorum Group Ltd. shares rose 30%, to $1.59, premarket after the clinical-stage biopharmaceutical company said the U.S. Food and Drug Administration granted orphan drug... | January 21, 2022